

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

CHANGE OF NAME

CONVEYING PARTY DATA

Name	Execution Date
Stem Cell Pharmaceuticals, Inc	09/12/2002

RECEIVING PARTY DATA

Name:	Kaleidos Pharma, Inc
Street Address:	562 First Avenue South
Internal Address:	Suite 700
City:	Seattle
State/Country:	WASHINGTON
Postal Code:	98104

PROPERTY NUMBERS Total: 4

Property Type	Number
Patent Number:	6486122
Application Number:	10039119
Patent Number:	5240912
Patent Number:	4863899

CORRESPONDENCE DATA

Fax Number: (650)969-8203

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: (650) 969-8300

Email: htran@imsciences.com

Correspondent Name: Hannah Tran

Address Line 1: 650 Castro Street

Address Line 2: Suite 220

Address Line 4: Mountain View, CALIFORNIA 94041

NAME OF SUBMITTER:

Hannah Tran

Total Attachments: 1

PATENT

500253889

REEL: 019122 FRAME: 0307

OP \$160.00 6486122

Jun 25 03 10:30a

Stem Cell Pharmaceuticals
206 332 0725

206 332-0725

P. 2

SEP-17-2002 15:05

Corp. System

360 357 6891 P.02/02

FILED
SECRETARY OF STATE

SEP 17 2002

STATE OF WASHINGTON

ARTICLES OF AMENDMENT

TO

AMENDED AND RESTATED ARTICLES OF INCORPORATION

OF

STEM CELL PHARMACEUTICALS, INC.

Pursuant to RCW 23B.10.060, the undersigned corporation adopts the following Articles of Amendment to its Amended and Restated Articles of Incorporation:

FIRST: The name of the corporation is Stem Cell Pharmaceuticals, Inc.

SECOND: The Amended and Restated Articles of Incorporation are hereby amended by deleting the current Article I and replacing it in its entirety with the following new Article I:

"ARTICLE I

Name

The name of this corporation is Kaleidos Pharma, Inc. (the "Corporation")."

THIRD: This amendment does not provide for an exchange, reclassification or cancellation of issued shares.

FOURTH: These Articles of Amendment were adopted and approved by the Board of Directors of this corporation on the 29th day of August, 2002, in accordance with the provisions of RCW 23B.10.020. Shareholder action was not required.

Dated September 12, 2002

STEM CELL PHARMACEUTICALS, INC.



Robert Littauer, Chief Executive Officer